Gan & Lee Pharmaceuticals doses first participant with once-weekly oral GLP-1 candidate

Gan & Lee Pharmaceuticals Co., Ltd. (SSE: 603087) has dosed the first participant in a first-in-human Phase I trial of GZC8072, an ultra-long-acting oral peptide glucagon-like peptide-1 receptor agonist formulated for once-weekly administration. The multicenter, randomized, double-blind, placebo-controlled study plans to enroll 112 participants, beginning with single ascending doses in healthy adults before moving to multiple ascending doses in people with overweight or obesity. GZC8072 has already received Chinese clinical-trial authorization for weight management and type 2 diabetes, giving Gan & Lee two potential metabolic indications around the same investigational molecule. The near-term test, however, is not whether GZC8072 produces blockbuster-level weight loss, but whether a peptide delivered orally can generate predictable exposure, acceptable tolerability and a pharmacokinetic profile capable of supporting the intended weekly dosing interval.

Gan & Lee developed GZC8072 through its wholly owned subsidiary Gan & Lee Pharmaceuticals (Shandong) Co., Ltd. and describes the candidate as a Class 1 innovative therapeutic biological product with proprietary intellectual property. The programme expands a metabolic pipeline that already includes injectable GLP-1 candidate bofanglutide, which reported positive Phase III weight-management results in China and Phase II results in the United States during 2026. That means GZC8072 is not simply an attempt to enter GLP-1 therapeutics for the first time; it is an effort to create a different dosing format within a company already building late-stage metabolic assets.

Why is once-weekly oral delivery a harder technical problem than simply making another GLP-1 medicine?

Peptides are generally difficult to deliver orally because the gastrointestinal system is designed to break proteins and peptides into smaller components before absorption. A swallowed peptide can therefore face degradation in the stomach and intestine, limited permeability across the intestinal wall and large variability in how much active drug reaches the bloodstream. Injectable formulations bypass much of that challenge by delivering the molecule directly into tissue.

Extending oral exposure sufficiently to support weekly dosing adds another difficulty. A drug taken once every seven days must either remain in the body long enough or produce a sufficiently durable pharmacological effect to avoid large swings between excessive early exposure and inadequate late-week activity. Phase I pharmacokinetic data will therefore matter as much as simple tolerability.

Gan & Lee’s trial design reflects that sequence. The single ascending dose portion in healthy adults can assess how exposure changes with dose and identify initial safety signals, while the multiple ascending dose phase in people with overweight or obesity can examine repeated weekly administration. Body-weight changes may eventually attract the most attention, but early human development needs to establish whether the dosing concept itself is pharmacologically workable.

If Gan & Lee achieves reliable weekly oral exposure, GZC8072 could offer a different convenience proposition from both injectable weekly GLP-1 medicines and oral products requiring much more frequent administration. That potential advantage remains hypothetical until human pharmacokinetic and efficacy data are available.

How does GZC8072 fit a Gan & Lee metabolic pipeline that already includes late-stage GLP-1 assets?

Gan & Lee’s most advanced obesity work gives the company a useful development base. Bofanglutide, a biweekly injectable GLP-1 receptor agonist, met primary endpoints in a pivotal Chinese Phase III weight-management study and a United States Phase II trial. The company reported 18.54% weight reduction at 52 weeks for a relevant bofanglutide treatment group in its China programme, positioning the molecule considerably closer to potential commercialization than GZC8072.

That creates portfolio optionality rather than straightforward duplication. Bofanglutide is testing whether less frequent injection can differentiate within an established therapeutic mechanism, while GZC8072 is attempting to change the administration route altogether. If both programmes ultimately succeed, Gan & Lee could address patients with different preferences rather than force the company to choose between an injectable and oral franchise.

The programmes also carry different development risks. Bofanglutide now faces regulatory and commercialization questions after later-stage efficacy testing, whereas GZC8072 must first prove basic human pharmacology. Investors should therefore avoid valuing the oral candidate as though it has inherited the clinical maturity of Gan & Lee’s injectable pipeline.

Portfolio depth can still create strategic value. Clinical expertise, endocrinology relationships and existing metabolic-development infrastructure can support multiple candidates, reducing the need to build an entirely new therapeutic organization around GZC8072.

Can Gan & Lee fund another metabolic programme without depending on immediate GZC8072 success?

Gan & Lee reported first-half 2026 revenue of approximately CNY2.22 billion, up 7.6% from CNY2.07 billion a year earlier. Net profit attributable to listed-company shareholders increased 1% to about CNY609.8 million, while operating cash flow rose approximately 74% to CNY432.3 million. Those results give the company an operating base very different from a pre-revenue obesity biotechnology company dependent entirely on outside financing.

Research spending is already a major part of Gan & Lee’s strategy. The company reported CNY1.34 billion of research and development investment during 2025, equivalent to roughly one-third of annual operating revenue. That level of investment indicates management is already funding a broad pipeline rather than building GZC8072 as a standalone project.

The trade-off is portfolio discipline. Metabolic drug development has become intensely competitive, and advancing several expensive programmes simultaneously can absorb substantial capital even for a profitable company. Gan & Lee needs each candidate to offer a sufficiently differentiated dosing, efficacy or commercial proposition rather than merely adding another GLP-1 asset to the pipeline.

GZC8072’s weekly oral concept provides that differentiation on paper. Phase I will determine whether the formulation can support it in humans.

What does Gan & Lee Pharmaceuticals’ share-price move after first dosing tell investors?

Gan & Lee shares closed at CNY67.89 on September 10, down approximately 1.5% from CNY68.91 on September 9 and about 5% below the September 3 close of CNY71.45. The stock remains within a wide 52-week range and has experienced sizable moves around pipeline announcements during recent weeks.

The September 10 decline should not automatically be interpreted as a negative verdict on GZC8072. First-patient dosing in Phase I rarely resolves enough clinical uncertainty to produce a durable valuation change, particularly for a company with marketed products and multiple later-stage development programmes. Broader market conditions and profit-taking can also affect daily price movements.

The more meaningful market catalyst will arrive when Gan & Lee discloses human pharmacokinetic, safety and tolerability results. A once-weekly oral formulation that fails to generate predictable exposure would undermine the programme before weight-loss efficacy becomes relevant. Conversely, evidence of consistent exposure across a full week could materially increase interest because it would validate the administration concept that makes GZC8072 unusual.

What evidence would move GZC8072 from an interesting formulation into a credible obesity asset?

The first requirement is acceptable safety across escalating doses. Gastrointestinal effects are common across the GLP-1 class, but oral peptide formulation may introduce additional questions around absorption variability and exposure. Gan & Lee will need a therapeutic window wide enough to maintain weekly activity without producing unacceptable peak-related tolerability problems.

Pharmacokinetics then become critical. Investors will want to see half-life, maximum concentration, overall exposure and variability between participants, along with evidence that repeated dosing does not create unexpected accumulation. Those data will determine whether once-weekly oral administration is genuinely supported by the molecule rather than simply targeted by the formulation.

Later trials will need to establish weight loss, glucose control and treatment persistence against increasingly demanding competitive benchmarks. GZC8072 is still far from those comparisons, which is why Phase I should be evaluated primarily as a formulation and pharmacology test.

Gan & Lee has already demonstrated that it can take metabolic assets into late-stage development. GZC8072 now asks whether the company can translate that experience into a dosing format that could be meaningfully more convenient. The answer begins with human exposure data, not with projections of the global obesity market.

Key takeaways on Gan & Lee Pharmaceuticals’ GZC8072 Phase I study

• Gan & Lee Pharmaceuticals has dosed the first participant with GZC8072.
• GZC8072 is an oral peptide GLP-1 receptor agonist designed for once-weekly use.
• The Phase I study plans to enroll 112 participants.
• The trial includes single ascending dose and multiple ascending dose portions.
• China has authorized clinical trials in both obesity or overweight and type 2 diabetes.
• GZC8072 remains an early-stage investigational medicine.
• Gan & Lee already has a later-stage injectable GLP-1 asset, bofanglutide.
• First-half 2026 revenue reached approximately CNY2.22 billion.
• Gan & Lee shares closed at CNY67.89 on September 10, down around 1.5%.
• Pharmacokinetics, safety and weekly exposure are the next meaningful proof points.